Abstract
hemostasis or with early rebleeding, 33 (76.7%) were treated with modified cyanoacrylate glue, 16 (37.2%) underwent surgery, and 3 (7.0%) were treated with selective transarterial embolization. The mean age of patients treated with NBCA + MS (23 males and 10 females) was 74.5 years. Modified cyanoacrylate was used in 24 patients during the first endoscopy and in 9 patients experiencing rebleeding. Overall, hemostasis was achieved in 26 of 33 patients (78.8%): 19 out of 24 (79.2%) during the first endoscopy and in 7 out of 9 (77.8%) among early rebleeders. Two patients (22.2%) not responding to cyanoacrylate treatment were treated with surgery or transarterial embolization. One patient had early rebleeding after treatment with cyanoacrylate. No late rebleeding during the follow-up or complications related to the glue injection were recorded.
INTRODUCTION
Acute upper gastrointestinal bleeding is the most com mon, potentially lifethreatening emergency occurring in gastroenterology departments [1] . The condition has an incidence ranging from approximately 50 to 150 per 100000 of the population each year, and the incidence is the highest in areas of the lowest socioeconomic status [1] . In the United States, acute upper gastrointestinal bleeding causes more than 300000 hospital admissions with an annual incidence of hospitalization equal to 1 per 1000 people [2] and a mortality rate of approxi mately 10% [3] . From a socioeconomic point of view, treating and preventing upper gastrointestinal bleeding costs many billions of dollars per year [4] . Despite the introduction of endoscopic therapies that reduce the rebleeding rate, the mortality rate has only slightly decreased over the last 30 years. This phenomenon is attributed to the increasing occurrence of upper gastrointestinal bleeding in the elderly. This group has a worse prognosis than others because of their greater use of antiplatelet medications or anticoagulants and their frequent comorbidities [5, 6] . Mortality has been reported to be lower in specialist units [7] . This difference is more likely to be due to adherence to protocols and guidelines than to technical developments.
Upper gastrointestinal bleeding can be caused by a wide variety of medical conditions. Peptic ulcers have been reported to be the cause of approximately 50% of upper gastrointestinal bleeding cases, whereas Mallory Weiss tears account for 5%15% of cases [8] . Esophageal varices are a common source of upper gastrointestinal bleeding, especially in patients with liver dysfunction and chronic alcoholism. Less frequent causes of upper gastrointestinal bleeding include erosive duodenitis, neoplasms, aortoenteric fistulas, vascular lesions, Dieulafoy's ulcers and prolapse gastropathy [9] . In our country, the large "Prometeostudy" [10] of patients with upper gastrointestinal bleeding recently showed that peptic lesions were the main cause of bleeding (duodenal ulcer 36.2%, gastric ulcer 29.6%, gastric/duodenal erosion 10.9%). Comorbidities were present in 83% and 52.4% of patients treated with acetyl salicylic acid or other nonsteroidal anti inflammatory drugs (NSAIDs), respectively, and 13.3% of patients had experienced previous episodes of upper gastrointestinal bleeding. Early rebleeding was observed in 5.4% of patients, and surgery was required in 14.3%. Bleedingrelated death occurred in 4.0% of patients. Endoscopic therapy is typically considered based on the characteristics and the classification of a bleeding ulcer. The Forrest classification is commonly used in Europe and Asia to describe bleeding lesions [11] . Stigmata can be used to predict the risk of further bleeding and the need for therapeutic intervention [12, 13] . Approximately 80% of upper gastrointestinal bleed ing episodes appear to stop bleeding spontaneously [11] ; the approximately 20% of episodes remaining either continue to bleed or will rebleed [14] . The recurrence of gastrointestinal hemorrhage is associated with an increased mortality rate, a greater need for surgery and blood transfusions, a prolonged hospital stay, and increased overall healthcare costs [15] .
Endoscopy within the first 24 h is considered the standard of care for the management of upper gastroin testinal bleeding [15] . Endoscopic therapy can be performed by a variety of methods, such as thermal coagulation, sclerotherapy, laser excision, and clip placement. All types of endo scopic therapy are generally considered equivalent, and a combination of methods is superior to an individual therapy [15] . Among the treatments that can be used during endoscopic treatment, cyanoacrylate glues have several advantages: they can be easily and rapidly applied, they are relatively painless, and they eliminate the need for suture removal [16] . Cyanoacrylate is a liquid tissue adhesive that has a wellestablished utility in the endoscopic management of gastrointestinal variceal bleeding [1719] , but its role in nonvariceal bleeding is less clear [1921] . This limitation is probably related to the limited experience in this area due to the availability of alternative modes of hemostasis, e.g., transarterial embolization, and to the potential side effects of endoscopic cyanoacrylate use in peptic ulcer disease [22] . In fact, despite the relatively safe use of cyanoacrylate glues for treating gastroesophageal variceal bleeding [23] , there are concerns about potential serious complications, parti cularly distant embolization. Given the possibility of this lifethreatening adverse event [21] , cyanoacrylate is considered a last resort for achieving endoscopic hemostasis in high surgical risk patients after conventional treatment methods have failed [19] . During the last 20 years, several cyanoacrylate form ulations have been developed. In our clinical practice, we have chosen Nbutyl2cyanoacrylate associated with methacryloxysulfolane (NBCA + MS: Glubran ® 2)
because of its peculiar characteristics. This formulation has hemostatic, sealing, bacteriostatic, adhesive and sclerosing properties. Polymerization begins 12 s after application and completes within 6090 s. The polymerization reaction generates a temperature of approximately 45 ℃ [24, 25] , which is lower than that of pure cyanoacrylates [16, 26] , and this formulation is the only cyanoacrylate glue approved for embolization therapy, as stated in the product's instructions for use.
In this paper, we retrospectively describe our personal experience using NBCA + MS injections for the management of (NVUGIB) after the failure of conventional endoscopic modalities.
MATERIALS AND METHODS
Between April 2008 and May 2015, 1177 patients were referred to our center for NVUGIB; 579 (49.2%) of these patients received endoscopic treatment.
Patients in whom initial hemostasis was not achieved or who had early rebleeding were treated with other measures, including surgery, selective transarterial embolization and/or cyanoacrylate glue injections ( Figure 1 possible precautions were taken to avoid intravasal penetration.
The technique involves injection through a sclero therapy catheter with a 21 to 25gauge retractable needle in or around actively bleeding points or non bleeding vessels (Figure 2 ).
NBCA + MS is applied deep in the submucosa with an injection needle in 0.5mL to 1.5mL boluses around the relevant vessel to "compress" from the outside of the bleeding vessel. The technique is then repeated for each bleeding vessel.
We have used this approach in 24 patients during their first endoscopy and in 9 patients who experienced rebleeding after the initial success of a conventional treatment. Bleeding recurrence was considered in the event of any one of the following: the vomiting of fresh blood, hypotension and melena, or the requirement for more than four units of blood in the 72h period after endoscopic treatment [23] . All 33 patients have received followup examin ations to detect eventual rebleeding. Currently, the average followup period is 37.6 mo (median, 40; range, 357).
RESULTS
Endoscopic hemostasis could not be achieved in 45 of 579 patients (7.8%) with conventional treatments, and early rebleeding occurred in 12 patients (2.1%). Of the 45 patients who did not exhibit initial hemostasis or who had early rebleeding, 33 (76.7%) were treated with cyanoacrylate glue, 16 (37.2%) underwent surgery (including 5 patients in whom cyanoacrylate therapy failed), and 3 (7.0%) were treated with selective transarterial embolization (including 2 patients in whom cyanoacrylate therapy failed).
The group of patients treated with NBCA + MS consisted of 23 males and 10 females; the mean patient age was 74.5 years (median, 78; range, 3894) (Tables 1 and 2 ).
The physical status of each patient was classified according to guidelines of the American Society of Anesthesiologists. Upon admission, the patients were categorized as follows: 1 patient, (3.0%) class Ⅰ; 9 patients, (27.3%) class Ⅱ; 20 patients, (60.6%) class Ⅲ; and 3 patients, (9.1%) class Ⅳ.
The presenting symptomatology was melena in 16 patients (48.5%), hematemesis in 16 patients (48.5%), and shock + hematemesis in 1 patient (3.0%). The average hemoglobin value at admission was 8.81 g/dL (range, 5.511.2). Seventeen (51.5%) patients had a duodenal ulcer, 6 (18.2%) had a gastric ulcer, 4 (12.1%) had an anastomotic ulcer, 2 (6.1%) had gastric postmucosectomy bleeding, 2 (6.1%) had a gastric Dieulafoy's ulcer, 1 (3.0%) had duodenal diverticular bleeding, and 1 (3.0%) had esophageal postmucosectomy bleeding.
Regarding the Forrest classification, 16 (48.5%) patients were grade Ⅰa, 6 were grade Ⅰb (18.2%), and 5 were grade Ⅱa (15.2%).
The initial endoscopic treatment consisted of epine phrine (Epi) + clip in 16 patients (48.5%), clip alone in 12 (36.4%), APC (Argon Plasma Coagulation) alone in 2 (6.1%), APC + Epi + clip in 1 (3.0%), Epi + APC in 1 (3.0%), and APC + clip in 1 (3.0%).
Glubran ® 2 was used in 24 patients during the first endoscopy and in 9 patients experiencing rebleeding after an initially successful treatment. Overall, hemostasis was achieved with NBCA + MS in 26 of 33 patients (78.8%). Hemostasis was successfully achieved with NBCA + MS during the first endoscopy in 19 of 24 patients (79.2%). Four patients (16.6%) who did not stop bleeding after the first endoscopy underwent surgery, and 1 (4.2%) was treated with selective transarterial embolization. One patient (4.1%) experienced early rebleeding after being treated with cyanoacrylate.
Of the 9 patients with early rebleeding, 7 (77.8%) achieved hemostasis with NBCA + MS usage, whereas 2 (22.2%) did not and were treated with surgery (1 patient) or transarterial embolization (1 patient).
No late rebleeding occurred during the followup period, and no complications related to the glue injections were recorded.
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Figure 2 a duodenal bleeding ulcer (Forrest type Ⅰb) (a); endoscopic hemostasis achieved with cyanoacrylate (B); and injection site evaluation after 3 d (C).
Table 1 Patients treated with cyanoacrylate injection during first endoscopy
DISCUSSION
Despite significant positive changes in recent years, NVUGIB remains a common, challenging and often life threatening emergency for gastroenterologists and endoscopists. Although there have been significant improvements in endoscopic and supportive therapies, the overall mortality rate remains approximately 10% and may even reach 35% in the elderly and in hospi talized patients with serious comorbidities [27] . In most cases, peptic ulcers spontaneously stop bleeding, and highdose intravenous proton pump inhibitors and endoscopic therapies for bleeding ulcers reduce recurrent bleeding risk and the need for surgery [28] . In approximately 4/5 th of all upper gastrointestinal episodes, bleeding stops spontaneously [11] , whereas in the remaining 1/5 th , the bleeding either continues or will recur, causing a rebleeding episode [14] . Thus, the main open question seems to involve the management of rebleeding.
Because the recurrence of gastrointestinal hemorr haging increases morbidity, mortality and cost [15] , the timely identification and aggressive management of patients at high risk for continued bleeding or rebleeding has become the major focus of upper gastrointestinal bleeding therapy [8] . Rebleeding after initial endotherapy can be con trolled in approximately 75% of patients with a second endoscopic treatment, which is safer than undergoing surgery [29] . While cyanoacrylate glue injections effectively control variceal bleeding, the role of the material in NVUGIB is less defined [30] . When administered by a suitably experienced endos copist for hemostasis, cyanoacrylate glue is considered a safe, inexpensive and effective salvage alternative to surgery when other measures have failed or if selective transarterial embolization is unavailable [1921, 31] . It is important to note that several different formulations of cyanoacrylate glue are available; these different formulations merit investigation as they may lead signi ficantly different results and safety profiles.
In variceal bleeding, the use of cyanoacrylate is very common and is included in several guidelines. However, few papers have report the results of its use in NVUGIB, and some are simple case descriptions or short case series [1920, 22] . No direct comparisons of the cyanoacrylate formulations are available.
To the best of our knowledge, the largest (126 patients) and only randomized study was performed by Lee et al [21] , who demonstrated significantly lower rebleeding rates in patients with Forrest type Ia lesions treated with a pure Nbutylcyanoacrylate glue (Histoacryl ® ) compared with a hypertonic saline adrenaline (HSE) injection; no overall benefits regarding hemostasis rates were observed in the other patients. However, although no complications followed HSE therapy, arterial embolization with infarction occurred in 2 patients treated with cyanoacrylate, and one of these patients died. Arterial embolization is considered the most dangerous complication of this treatment; therefore, this therapy is typically recommended as a final measure due to the potentially fatal adverse effects [21] . In contrast, in other published papers, com plication rates are typically negligible [19, 20, 22] , mirroring the low rates of complications recently reported with the use of cyanoacrylate for varices [23, 30] . Our retrospective series of 33 cases supports the efficacy (78.8% success rate) and safety (no side effects) of the modified cyanoacrylate formulation (NBCA + MS) used in our Digestive Endoscopy and Gastroenterology Unit. Compared with other similar, but shorter, case series [19, 20, 22] , the success rate observed in our patients might be due to the fact that we used the glue exclusively as a secondline therapy; in addition, we used a different methodology, i.e., injection only, and our patients had different baseline diseases.
Although our results were obtained from a retro spective series, in our opinion, it would be possible to hypothesize that the lack of complications might be at least partly derived from our long experience in treating variceal bleeding with this product that has been largely documented in digestive endoscopy [29, 3234] . In addition, the differences among the cyano acrylate formulations might be crucial. In particular, polymerization time and temperature may play a role in this respect. The polymerization time depends on the amount of injected liquid. However, NBCA + MS generally begins to polymerize 1 s to 2 s after application, and the polymerization is complete within 60 s to 90 s. In contrast, other cyanoacrylates take longer (150180 s) to polymerize [16, 26] , and these glues only reach maximum mechanical strength upon complete polymerization. The differences regarding the temperature generated by the polymerization reaction appear to be more important than polymerization time. NBCA + MS generates a temperature of approximately 45 ℃ and thus causes very limited damage to the surrounding tissue [24, 25] . In contrast, other cyanoa crylates generate temperatures of 8090 ℃, causing more inflammation and, rarely, tissue necrosis and deep ulcers or fistulas [35] . Some authors consider surgery or selective transarterial embolization to be preferred methods for controlling rebleeding, even though it is accepted that treatments should be largely based on patient comorbidities and surgical risk [22] . In our opinion, NBCA + MS should be implemented before surgery because it is cheaper, is associated with fewer complications, and is very effective (77.8% in our early rebleeding patients), as previously reported by others [19] . Our retrospective observational study indicates that the formulation of cyanoacrylic glue associated with methacryloxysulfolane used in our department was safe and effective for treating NVUGIB after the failure of conventional treatment modalities. As our results were obtained from a medium size retrospective series, no definitive conclusions can be drawn. In our experience, the glue has been safe and has not caused any side effects. Therefore, in agreement with the literature [21] , we suggest its use in high surgical risk patients for endoscopic hemostasis as a last resort, given the possibility of lifethreatening adverse events. Finally we consider important to underline that our results are derived from a retrospective observational study: it is well known that retrospective studies have a limited validity compared to randomized clinical trials because the characteristics of the subjects included, the data collected and measured outcomes are defined after the end of the recruitment. Our data have been collected in order to obtain a good level of quality, but, in retrospective studies this cannot be guaranteed. Furthermore, observational studies tend both to overestimate the effects of treatment and to have greater variability in effect estimates because of residual confounding. Hence our results should be read taking into account these possible biases. In our opinion a randomized clinical trial comparing NBCA + MS with the current standard rescue treatments in selected populations is therefore highly advisable.
In the case of positive outcomes, further com parisons with other cyanoacrylate formulations might be useful for establishing the role of NBCA + MS in patients with NVUGIB after conventional treatments have failed and for clarifying the longterm differences
